-+ 0.00%
-+ 0.00%
-+ 0.00%

ARCUTIS ANNOUNCES POSITIVE TOPLINE RESULTS FOR INTEGUMENT-INFANT PHASE 2 TRIAL OF ZORYVE® (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH MILD TO MODERATE ATOPIC DERMATITIS

Reuters·02/02/2026 13:00:01

Please log in to view news